World's Best Scientists 2026 revealed!
Award Badge
Medicine
Germany
2023

D-Index & Metrics

Medicine

D-Index
129
Citations
81429
World Ranking
2540
National Ranking
124

Peter A. Fasching publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Peter A. Fasching sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,167 publications — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Peter A. Fasching D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Peter A. Fasching sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 129 D-Index — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Germany Leader Award

Overview

Peter A. Fasching is affiliated with the University of Erlangen-Nuremberg in Germany. Their research spans multiple fields with a strong focus on medicine, particularly oncology and cancer research. They have published extensively in subfields such as pulmonary and respiratory medicine, genetics, and molecular biology.

The scientist's work covers key topics including:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • BRCA gene mutations in cancer
  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers

Frequent co-authors collaborating with Peter A. Fasching include:

  • Andreas Schneeweiß
  • Michael Untch
  • Volkmar Müller
  • Matthias W. Beckmann
  • Tanja Fehm

The scientist has contributed to a range of prominent publication venues, often publishing in:

  • Cancer Research
  • Geburtshilfe und Frauenheilkunde
  • Annals of Oncology
  • Senologie - Zeitschrift für Mammadiagnostik und -therapie
  • Journal of Clinical Oncology

Among notable recent papers associated with the broader research community and topics related to Fasching's expertise are:

  • Pembrolizumab for Early Triple-Negative Breast Cancer, 2020, New England Journal of Medicine
  • Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women, 2021, New England Journal of Medicine
  • Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses, 2020, Nature Genetics
  • Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials, 2021, The Lancet Oncology
  • Genetic insights into biological mechanisms governing human ovarian ageing, 2021, Nature

Peter A. Fasching's research outputs contribute primarily to understanding the molecular and clinical facets of cancer, with a dominant emphasis on breast cancer therapies and genetic factors implicated in oncological diseases.

Best Publications

  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Patricia Cortazar;Lijun Zhang;Michael Untch;Keyur Mehta

  • Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

    Gunter von Minckwitz;Michael Untch;Jens-Uwe Blohmer;Serban D. Costa

  • Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

    Gunter Von Minckwitz;Chiun Sheng Huang;Max S. Mano;Sibylle Loibl

  • Pembrolizumab for Early Triple-Negative Breast Cancer.

    Peter Schmid;Javier Cortes;Lajos Pusztai;Heather McArthur

  • Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

    Carsten Denkert;Gunter von Minckwitz;Silvia Darb-Esfahani;Bianca Lederer

  • Association analysis identifies 65 new breast cancer risk loci

    Kyriaki Michailidou;Kyriaki Michailidou;Sara Lindström;Sara Lindström;Joe Dennis;Jonathan Beesley

  • Large-scale genotyping identifies 41 new loci associated with breast cancer risk

    Kyriaki Michailidou;Per Hall;Anna Gonzalez-Neira;Maya Ghoussaini

  • Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

    Gunter von Minckwitz;Andreas Schneeweiss;Sibylle Loibl;Christoph Salat

  • Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.

    Celeste Leigh Pearce;Claire Templeman;Mary Anne Rossing;Alice Lee

  • RAD51B in Familial Breast Cancer

    Liisa M. Pelttari;Sofia Khan;Mikko Vuorela;Johanna I. Kiiski

  • Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

    Dennis J. Slamon;Patrick Neven;Stephen Chia;Peter A. Fasching

  • Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

    Nasim Mavaddat;Kyriaki Michailidou;Kyriaki Michailidou;Joe Dennis;Michael Lush

  • Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies

    Xiaohong R. Yang;Jenny Chang-Claude;Ellen L. Goode;Fergus J. Couch

  • Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk

    Ganna Chornokur;Hui-Yi Lin;Jonathan P. Tyrer;Kate Lawrenson

  • Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women

    Leila Dorling;Sara Carvalho;Jamie Allen

  • Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer

    Fergus J. Couch;Steven N. Hart;Priyanka Sharma;Amanda Ewart Toland

  • Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients

    Brigitte Rack;Christian Schindlbeck;Julia Jückstock;Ulrich Andergassen

  • Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

    Kyriaki Michailidou;Jonathan Beesley;Sara Lindstrom;Sander Canisius

  • Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study

    Michael Untch;Mahdi Rezai;Sibylle Loibl;Peter A. Fasching

  • Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

    Dennis J. Slamon;Patrick Neven;Stephen Chia;Peter A. Fasching

Frequent Co-Authors

Matthias W. Beckmann
Matthias W. Beckmann University of Erlangen-Nuremberg
Graham G. Giles
Graham G. Giles University of Melbourne
Jenny Chang-Claude
Jenny Chang-Claude German Cancer Research Center
Andreas Schneeweiss
Andreas Schneeweiss German Cancer Research Center
Hiltrud Brauch
Hiltrud Brauch German Cancer Research Center
Roger L. Milne
Roger L. Milne Cancer Council Victoria
Paul D.P. Pharoah
Paul D.P. Pharoah University of Cambridge
Melissa C. Southey
Melissa C. Southey Monash University
Tanja Fehm
Tanja Fehm Heinrich Heine University Düsseldorf

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine but aren’t sure about becoming a physician, there are several flexible online degree options available. These programs can help you advance in healthcare, management, or nursing—even if you have a busy schedule or need to study remotely.

Healthcare management is a strong alternative to clinical practice. The top cahme accredited mha programs allow you to gain leadership skills for roles in hospitals, clinics, and other healthcare organizations.

For registered nurses wanting to enhance their credentials, the rn to bsn online no clinicals options are ideal. These programs offer academic advancement without the need for additional in-person clinical experience.

If you aim for the highest levels in nursing, consider doctoral pathways. The shortest online dnp program lets you earn a Doctor of Nursing Practice degree far quicker than traditional on-campus routes. Alternatively, if you prefer a less intensive approach, the easiest dnp program online can help you achieve doctorate status with greater flexibility.

Each of these online pathways offers new opportunities for growth in healthcare and supports a variety of professional goals.

Best Scientists Citing Peter A. Fasching

Trending Scientists

Recently Published Articles